Cancer screening and diagnostic tests provider Exact Sciences Corp (NASDAQ: EXAS) on Monday announced the expiration of the Hart-Scott-Rodino Antitrust Act waiting period for its previously disclosed license agreement with Freenome, granting the company exclusive US rights to Freenome's blood-based colorectal cancer (CRC) screening tests.

The license expands Exact Sciences' cancer screening portfolio, complementing existing offerings including Cologuard and Oncotype DX, while exclusivity remains contingent on Freenome receiving first-line FDA approval.

Following the completion of the agreement, Exact Sciences updated its full-year 2025 adjusted EBITDA guidance to reflect the initial USD75m cash payment under the license. Adjusted EBITDA is now expected at USD395-USD405m, down USD75m from prior guidance, with total revenue unchanged at USD3.220-USD3.235bn. Screening revenue is projected at USD2.510-USD2.520bn and Precision Oncology at USD710-USD715m.

Exact Sciences continues to develop a broad pipeline of advanced cancer diagnostics, including multi-cancer early detection with Cancerguard and molecular residual disease monitoring via Oncodetect, aiming to improve clinical outcomes and enhance patient decision-making.